Recommended offer

Statement by the Board of Directors of Calliditas Therapeutics AB in relation to the public offer by Asahi Kasei Corporation

The Board of Directors of Calliditas Therapeutics AB unanimously recommends that the shareholders and holders of American Depositary Shares (“ADS”) of Calliditas Therapeutics AB accept the public tender offer by Asahi Kasei Corporation.

Asahi Kasei Corporation announced on May 28, 2024, a public cash offer to acquire all shares in Calliditas (the “Shares”) for SEK 208 in cash per Share (the “Offer”). The Offer will also include a concurrent offer by the Offeror to acquire all American Depositary Shares, each representing two Shares in Calliditas, for SEK 416 in cash per ADS, which will be conducted pursuant to the securities rules of the United States.

This statement is made by the Board of Directors of Calliditas Therapeutics AB pursuant to section II.19 of the Nasdaq Stockholm takeover rules (“Section II.19”) and Regulation 14D under the Securities Exchange Act of 1934, as amended (together with Section II.19, the “Takeover Rules”).

On 16 September 2024, Asahi Kasei announced that it controlled 98.38 per cent of all shares in Calliditas following the Offer, which is now closed. Asahi Kasei has initiated a compulsory buy-out procedure in respect of the shares in Calliditas not owned by Asahi Kasei in accordance with the Swedish Companies Act.

More information can be found on the bidder’s website: https://www.asahi-kasei.com/announcement/01.html